A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells - Cancer Gene Therapy
- ️Rooney, Cliona M
- ️Fri Dec 19 2003
Riddell SR, Greenberg PD . Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol. 1995;13:545–586.
Rooney CM, Aguilar LK, Huls MH, Brenner MK, Heslop HE . Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001;258:221–229.
Perez-Diez A, Marincola FM . Immunotherapy against antigenic tumors: a game with a lot of players. Cell Mol Life Sci. 2002;59:230–240.
Poppema S, van den Berg A . Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol. 2000;10:345–350.
Nestle FO . Dendritic cell vaccination for cancer therapy. Oncogene. 2000;19:6673–6679.
Mosmann TR, Li L, Sad S . Functions of CD8 T-cell subsets secreting different cytokine patterns. Semin Immunol. 1997;9:87–92.
Dong C, Flavell RA . Th1 and Th2 cells. Curr Opin Hematol. 2001;8:47.
Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170:827–845.
Stern AS, Podlaski FJ, Hulmes JD, et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA. 1990;87:6808–6812.
Banks RE, Patel PM, Selby PJ . Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer. 1995;71:655–659.
Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J . Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995;87:581–586.
Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90:2541–2548.
Herbst H, Dallenback F, Hummel M, et al. Epstein–Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Aci USA. 1991;88:4766–4770.
Roskrow MA, Suzuki N, Gan Y-J, et al. EBV-specific cytotoxic T lymphocytes for the treatment of patients with EBV positive relapsed Hodgkin's disease. Blood. 1998;91:2925–2934.
Newcom SR, Gu L . Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. J Clin Pathol. 1995;48:160–163.
Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2001;97:250–255.
Peh SC, Kim LH, Poppema S . TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma. Am J Surg Pathol. 2001;25:925–929.
Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, Graham FL . Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther. 1996;7:1995–2002.
Wolf J, Kapp U, Bohlen H, et al. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin–Reed Sternberg cells. Blood. 1996;87:3418–3428.
Drexler HG, Gaedicke G, Lok MS, Diehl V, Minowada J . Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles. Leuk Res. 1986;10:487–500.
Anderson R, Macdonald I, Corbett T, Hacking G, Lowdell MW, Prentice HG . Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus. Hum Gene Ther. 1997;8:1125–1135.
Riviere I, Brose K, Mulligan RC . Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA. 1995;92:6733–6737.
Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK . Epstein–Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002;99:2009–2016.
Bollard CM, Rossig C, Calonge MJ, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002;99:3179–3187.
Jin Y, Fuller L, Carreno M, Esquenazi V, Tzakis AG, Miller J . The regulation of phenotype and function of human liver CD3+/CD56+ lymphocytes, and cells that also co-express CD8 by IL-2, IL-12 and anti-CD3 monoclonal antibody. Hum Immunol. 1998;59:352–362.
Jabs WJ, Hennig H, Kittel M, et al. Normalized quantification by real-time PCR of Epstein–Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. J Clin Microbiol. 2001;39:564–569.
Livak KJ, Schmittgen TD . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408.
Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB . Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol. 1997;158:3325–3334.
Pollok KE, van der Loo JC, Cooper RJ, Kennedy L, Williams DA . Costimulation of transduced T lymphocytes via T cell receptor–CD3 complex and CD28 leads to increased transcription of integrated retrovirus. Hum Gene Ther. 1999;10:2221–2236.
Gorelik L, Constant S, Flavell RA . Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med. 2002;195:1499–1505.
Kemp RA, Ronchese F . Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol. 2001;167:6497–6502.
Stewart JP, Rooney CM . The interleukin-10 homolog encoded by Epstein–Barr virus enhances the reactivation of virus-specific cytotoxic T cell and HLA-unrestricted killer cell responses. Virology. 1992;191:773–782.
Santin AD, Hermonat PL, Ravaggi A, et al. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol. 2000;74:4729–4737.
Colombo MP, Trinchieri G . Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13:155–168.
Kang WK, Park C, Yoon HL, et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther. 2001;12:671–684.
Harries M, Phillipps N, Anderson R, Prentice G, Collins M . Comparison of bicistronic retroviral vectors containing internal ribosome entry sites (IRES) using expression of human interleukin-12 (IL-12) as a readout. J Gene Med. 2000;2:243–249.
Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP . Epstein–Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res. 2001;61:6219–6226.
Smits HH, van Rietschoten JG, Hilkens CM, et al. IL-12-induced reversal of human Th2 cells is accompanied by full restoration of IL-12 responsiveness and loss of GATA-3 expression. Eur J Immunol. 2001;31:1055–1065.
Sudarshan C, Galon J, Zhou Y, O'Shea JJ . TGF-beta does not inhibit IL-12- and IL-2-induced activation of Janus kinases and STATs. J Immunol. 1999;162:2974–2981.
Xu J, Menezes J, Prasad U, Ahmad A . Elevated serum levels of transforming growth factor beta 1 in Epstein–Barr virus-associated nasopharyngeal carcinoma patients. Int J Cancer. 1999;84:396–399.
Maggi E, Manetti R, Annunziato F, Romagnani S . CD8+ T lymphocytes producing Th2-type cytokines (Tc2) in HIV-infected individuals. J Biol Regul Homeost Agents. 1995;9:78–81.
Kinsella TM, Nolan GP . Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther. 1996;7:1405–1413.
Rickinson AB, Moss DJ, Allen DJ, Wallace LE, Rowe M, Epstein MA . Reactivation of Epstein–Barr virus-specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line. Int J Cancer. 1981;27:593–601.